New Data Confirms Early Implantation of Impella 2.5 Prior to PCI Biotech Improves Survival in Shock Patients
11/11/2011 6:27:37 AM
DANVERS, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced new results from a multicenter retrospective study demonstrating that early initiation of support with Impella® 2.5 prior to revascularization improves survival in emergent patients as compared to those receiving Impella 2.5 support after percutaneous coronary intervention (PCI). Specifically, the analysis demonstrated that shock patients that received Impella before revascularization had a higher survival rate (65% vs. 39%, p=0.007 respectively, N=119).